Abiopharma

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Triple Flag Completes Acquisition of US$440 Million Gold Stream on the Ravenswood Gold Mine

Share Buy Back - Daily Share Buy-Back Notice: Share Buy Back - Daily Share Buy-Back Notice

General Announcement: Early Termination of Lease at Concor Park Campus

High Templar Tech Announces Preliminary Results of Modified Dutch Auction Tender Offer

AMC Entertainment Holdings, Inc. Announces Closing of $200 Million Registered Direct Offering of Common Stock

Additional extension of the memorandum of understanding between Delek Israel and HOT Mobile until June 30, 2026

Share Buy Back - Daily Share Buy-Back Notice: Share Buy Back - Daily Share Buy-Back Notice

KKR Announces Intra-Quarter Update

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10)Advanced Triple-Negative Breast Cancer (TNBC)